Cite
HARVARD Citation
Chamorro-de-Vega, E. et al. (n.d.). Effectiveness and Safety of Ombitasvir-Paritaprevir/Ritonavir and Dasabuvir With or Without Ribavirin for HCV Genotype 1 Infection for 12 Weeks Under Routine Clinical Practice. Annals of pharmacotherapy. pp. 901-908. [Online].